Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

2,741.28

1,559.05

2,063.83

2,237.01

3,118.70

2,327.20

2,799.73

Other Operating Income

0.00

Total Operating income

2,741.28

1,559.05

2,063.83

2,237.01

3,118.70

2,327.20

2,799.73

Raw Material Cost

1,584.95

1,208.41

1,370.78

1,503.55

1,750.51

1,588.56

1,508.63

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

6.63

9.93

6.13

8.50

7.19

9.48

9.17

Selling and Distribution Expenses

211.99

208.85

143.40

191.01

148.07

284.30

151.42

Other Expenses

8.08

5.31

4.49

3.99

6.25

11.11

1.55

Total Expenditure (Excl Depreciation)

1,884.40

1,480.32

1,565.21

1,742.91

1,968.23

1,993.46

1,684.75

Operating Profit (PBDIT) excl Other Income

856.9

78.7

498.6

494.09999999999997

1150.5

333.7

1115

Other Income

28.51

29.71

38.56

54.38

43.50

31.58

41.96

Operating Profit (PBDIT)

860.17

127.42

561.68

566.65

1,225.51

385.17

1,159.02

Interest

6.63

9.93

6.13

8.50

7.19

9.48

9.17

Exceptional Items

-7.26

-1.98

-0.05

-0.10

-7.63

6.27

-0.02

Gross Profit (PBDT)

1,156.33

350.63

693.05

733.46

1,368.19

738.64

1,291.11

Depreciation

0.00

32.29

32.26

25.89

Profit Before Tax

846.28

83.22

523.21

525.79

1,178.43

356.08

1,123.93

Tax

135.93

42.79

94.00

88.61

169.15

72.95

156.38

Provisions and contingencies

0.00

Profit After Tax

743.48

29.29

687.04

442.53

999.78

290.32

965.15

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

743.48

29.29

687.04

442.53

999.78

290.32

965.15

Share in Profit of Associates

0.00

Minority Interest

-3.34

-19.31

-1.73

-8.02

13.71

-12.55

4.26

Other related items

0.00

Consolidated Net Profit

740.14

9.98

685.31

434.50

1,013.50

277.76

969.40

Equity Capital

0.00

Face Value

1.0

Reserves

15,212.57

14,539.50

14,472.25

14,624.56

15,262.92

14,271.73

14,021.30

Earnings per share (EPS)

1.23

0.05

1.14

0.73

1.66

0.48

1.6

Diluted Earnings per share

1.23

0.05

1.14

0.73

1.66

0.48

1.6

Operating Profit Margin (Excl OI)

30.34%

4.2%

23.78%

21.46%

36.87%

14.08%

38.97%

Gross Profit Margin

30.87%

7.41%

26.92%

24.95%

38.82%

16.41%

41.07%

PAT Margin

27.12%

1.88%

33.29%

19.78%

32.06%

12.47%

34.47%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is 75.84% vs -24.46% in Dec 2025

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 7,301.00% vs -98.54% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 751.28% vs -81.32% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is -33.33% vs 62.30% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

2,741.28

Other Operating Income

0.00

Total Operating income

2,741.28

Raw Material Cost

1,584.95

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

6.63

Selling and Distribution Expenses

211.99

Other Expenses

8.08

0.00

8.08

Total Expenditure (Excl Depreciation)

1,884.40

Operating Profit (PBDIT) excl Other Income

856.88

0.00

856.88

Other Income

28.51

Operating Profit (PBDIT)

860.17

Interest

6.63

Exceptional Items

-7.26

Gross Profit (PBDT)

1,156.33

Depreciation

0.00

Profit Before Tax

846.28

Tax

135.93

Provisions and contingencies

0.00

Profit After Tax

743.48

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

743.48

Share in Profit of Associates

0.00

Minority Interest

-3.34

Other related items

0.00

Consolidated Net Profit

740.14

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

15,212.57

Earnings per share (EPS)

1.23

Diluted Earnings per share

1.23

Operating Profit Margin (Excl OI)

30.34%

0.00

30.34%

Gross Profit Margin

30.87%

0.00

30.87%

PAT Margin

27.12%

0.00

27.12%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 274.13 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 75.84% vs -24.46% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -12.10% vs -1.64% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 74.01 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 7,301.00% vs -98.54% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -26.98% vs 1.47% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 83.17 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 751.28% vs -81.32% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -29.64% vs 1.23% in Mar 2025

Quarterly - Interest

Interest 0.66 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -33.33% vs 62.30% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -8.33% vs -25.77% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 30.34%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025